Johnson & Johnson Submits Supplemental Biologics License Application To FDA Seeking Approval Of TREMFYA (Guselkumab) For Treatment Of Adults With Moderately To Severely Active Ulcerative Colitis
Portfolio Pulse from Benzinga Newsdesk
Johnson & Johnson has submitted a Supplemental Biologics License Application to the FDA for the approval of TREMFYA (Guselkumab) for the treatment of adults with moderately to severely active ulcerative colitis.
March 11, 2024 | 8:35 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Johnson & Johnson's submission for TREMFYA's approval for ulcerative colitis treatment could expand its market and usage.
The submission for TREMFYA's new application to the FDA indicates Johnson & Johnson's efforts to expand the drug's usage into new therapeutic areas. If approved, this could lead to increased sales and a broader market presence for TREMFYA, positively impacting JNJ's stock in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90